Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities

    NEXT STORY
    Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer
    PREV STORY
    Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Emerald Bioscience Appoints Chief Medical Officer and Executive Director, Clinical Operations

    author_avatar
    NASDAQ Market News

    Trinitas-St. Joseph’s Behavioral Health Network Offers Innovative Alternative Treatment for Depression

    author_avatar
    NASDAQ Market News

    BeyondSpring to Participate in Joseph Gunnar’s Pioneers 2017 Conference on May 2 in New York

    NEW YORK, April 26, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical ...

    author_avatar
    NASDAQ Market News